Literature DB >> 32439566

Molecular characteristics and risk factors associated with linezolid-resistant Enterococcus faecalis infection in Southwest China.

Jiaqi Zou1, Yun Xia2.   

Abstract

BACKGROUND: Linezolid is one of the last lines of defence for Gram-positive bacteria, and the increasing emergence of linezolid-resistant enterococci (LRE) has become an important problem in nosocomial infections.
OBJECTIVES: This study aimed to explore the mechanisms of linezolid resistance and analyse risk factors for the infection with LRE.
METHODS: The known resistance mechanisms of linezolid were detected by polymerase chain reaction (PCR). Clinical data of patients with LRE infection were collected from the electronic medical record system. Risk factors associated with LRE were determined by comparing two case groups (LRE group and linezolid-susceptible enterococci [LSE] group) with the control group (without enterococci infection) at a ratio of 1:1:2. Multivariate logistic regression models were used to evaluate independent risk factors for acquiring LRE and LSE.
RESULTS: A total of 85 (4.5%) LRE isolates were detected during a 5-year period. The main resistance mechanism was acquisition of the transferable gene optrA (98.8%), followed by the L4 protein mutation (37.7%) and L3 protein mutation (4.7%). In our study, 85 LRE cases, 85 LSE cases, and 170 controls were then enrolled; multivariable analyses indicated that transfer from another hospital (odds ratio [OR], 3.2; 95% confidence interval [CI], 1.5-7.3; P = 0.004), malignant tumour (OR, 3.7; 95% CI, 1.6-8.8; P = 0.003), polymicrobial infection (OR, 12.2; 95% CI, 1.4-106.2; P = 0.023), and urinary tract infections (OR, 42.7; 95% CI, 11.4-159.3; P = 0.000) were independent predictors for acquiring LRE. In addition, polymicrobial infections (OR, 43.3; 95% CI, 14.1-132.8; P = 0.000), total length of hospital stay (≥30 days) (OR, 5.7; 95% CI, 1.9-17.3; P = 0.002) and exposure to glycopeptide (OR, 6.6; 95% CI, 1.1-38.8; P = 0.035) were independently associated with LSE infections.
CONCLUSIONS: Proper antibiotic management programs and monitoring of patient risk factors are necessary to control LRE infections.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Enterococcus faecalis; Linezolid resistance; Risk factor; optrA

Mesh:

Substances:

Year:  2020        PMID: 32439566     DOI: 10.1016/j.jgar.2020.03.027

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  4 in total

1.  Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance.

Authors:  Lifang Jiang; Na Xie; Mingtao Chen; Yanyan Liu; Shuaishuai Wang; Jun Mao; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-02-09       Impact factor: 5.640

2.  Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model.

Authors:  Shuaishuai Wang; Huiping Liu; Jun Mao; Yu Peng; Yisong Yan; Yaowen Li; Na Zhang; Lifang Jiang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

3.  Mobile Oxazolidinone Resistance Genes in Gram-Positive and Gram-Negative Bacteria.

Authors:  Stefan Schwarz; Wanjiang Zhang; Xiang-Dang Du; Henrike Krüger; Andrea T Feßler; Shizhen Ma; Yao Zhu; Congming Wu; Jianzhong Shen; Yang Wang
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

4.  Evaluation of CHROMagar™ LIN-R for the Screening of Linezolid Resistant Staphylococci from Positive Blood Cultures and Nasal Swab Screening Samples.

Authors:  Delphine Girlich; Liliana Mihaila; Vincent Cattoir; Frédéric Laurent; Christine Begasse; Florence David; Carole-Ann Metro; Laurent Dortet
Journal:  Antibiotics (Basel)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.